FLOT1 and myeloid sarcoma: Additional follow-up sera of the patients were analyzed when available and showed that the anti-flotillin-1/2 titers of P1, P2, and P4 were unaltered over a period of 18, 24, and 72 months, respectively, despite initiation of disease-modifying treatment for MS (interferon-β or natalizumab).